Date Title Description PDF
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download

Pages

Date Title Description PDF
29 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 December and 28 December 2023 Download
22 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 December and 21 December 2023 Download
15 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 11 December and 14 December 2023 Download
11 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 December and 8 December 2023 Download
01 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 24 November and 30 November 2023 Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages